PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1170393
PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1170393
We see great future treatment opportunity for the NMOSD market because of the launch of the emerging therapies like Ravulizumab (Alexion Pharmaceuticals), Telitacicept (RC-Pharma), SHR1459 (Reistone Biopharma) and other potential therapies, providing the global solution for "optic neuritis with spinal cord manifestations and other neurologic disorders associated with the serum aquaporin-4 immunoglobulin G antibodies".
Neuromyelitis Optica Spectrum Disorder (NMOSD) is an inflammatory, demyelinating, antibody-mediated disease of the central nervous system (CNS) that predominantly targets the optic nerves, brainstem, and spinal cord. The NMOSD involves aquaporin 4 (AQP4) which is a membrane-bound protein with a high concentration in a certain region of the central nervous system, such as the optic nerve, and the spinal cord which is being attacked by the IgG antibody.
NMOSD can be categorized into two pathophysiological entities depending on the presence or absence of AQP4-Ab. In approx. 80% of cases, AQP4-Ab can be detected, which causes a primarily astrocytopathic disease. Interestingly, in about 50% of the AQP4-Ab seronegative NMOSD patients autoantibodies against myelin-oligodendrocyte-glycoprotein (MOG-Ab) can be seen, whose pathomorphological correlate is primarily oligodendrocytopathic.AQP4-IgG testing in cases with good clinical reason to suspect NMOSD may be of value and that a positive AQP4-IgG test lessens the clinical and radiologic requirements for a diagnosis of NMOSD; these principles guided the development of the diagnostic criteria proposed by the IPND. The 2015 diagnostic criteria outline a stratified diagnosis based on the presence or absence of serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG), which are highly specific for NMOSD. Most-though not all-patients with NMO have detectable serum antibodies that target AQP4-IgG.
As per estimates, the United States accounted for the highest prevalence of Neuromyelitis Optica Spectrum Disorder (NMOSD) cases are expected to reach ~18,152 by 2032 during the study period.
The current therapies market to treat Neuromyelitis Optica Spectrum Disorder (NMOSD) has transformed in recent years with new options for a disease that have the potential to significantly improve patient outcomes. In countries where all three of these new treatments are approved for clinical use, clinicians are now faced with a changing landscape of options to offer their patients with NMOSD, who might have different priorities among efficacy, safety, cost, monitoring burden, and logistics. The current therapies market to treat NMOSD is large as 100% of the affected population will be prescribed with immunosuppressive agents as the first line of therapy.
Currently, three medications have been approved for the treatment of NMOSD and these include satralizumab, eculizumab and inebilizumab. These medications have shown promising results concerning short-term efficacy. However, there is no data on long-term safety and efficacy in NMOSD patients and their efficacy in AQP4-Ab negative NMOSD patients is not yet known. At present, drugs such as azathioprine, rituximab and mycophenolate mofetil are being used to prevent relapse for patients with NMOSD. However, recurrent relapse in patients with NMOSD is still common which is due to the lack of specific therapeutic target. Additionally, some patients are intolerable to certain treatments due to their side effects, such as avascular necrosis of femoral head and hepatic impairment.
The Neuromyelitis Optica Spectrum Disorder (NMOSD) therapeutics market is expected to increase at a significant rate during the figure time frame, 2021 to 2032. In 2021, the market is developing at a consistent rate and the market is relied upon to ascend over the projected horizon with the rise in adoption strategies by key market players. The therapy market is expected to experience high growth throughout our study period, increasing from USD 362 million in 2018 to USD 2.64 billion in 2032, representing compound annual growth (CAGR) of 15.25%. Primary drivers of this growth will be the uptake of the existing drugs i.e., Soliris/Eculizumab (Alexion), Enspryng/Satralizumab (Roche), and Uplinza/Inebilizumab (Horizon) as well as the launch of the new drugs i.e., Ravulizumab (Alexion) Telitacicept (RemeGen).